EnteroBiotix, a Glasgow-based biotech firm specializing in microbiome therapeutics, has successfully closed a funding round totaling £27M (approximately €31.46M). This round combines £15.7M (approximately €18.29M) in fresh equity with the conversion of £11.6M (approximately €13.51M) of loan notes into equity.
The funding was contributed by new and existing investors, including US-based life science investors Thairm Bio and Kineticos Life Sciences, with additional support from the Scottish National Investment Bank.
Clinical-Stage Development and Strategic Partnerships
Founded in 2017, EnteroBiotix is at the forefront of developing “best-in-class” microbial therapeutics for patients with significant unmet medical needs. The company leverages its product platform to offer customized, high-diversity products aimed at fortifying and restoring the microbiome. A strategic partnership with Imperial College London supports clinical trials in critical medical areas, including a Phase 2 clinical trial targeting Irritable Bowel Syndrome (IBS) and a completed Phase 2 study focusing on liver cirrhosis.
Advertisement
Utilizing Capital for Key Clinical Trials
The newly acquired funds will be directed towards advancing the development of EnteroBiotix’s primary product candidate, EBX-102-02, through a Phase 2 clinical trial for IBS, conducted in collaboration with the Functional Gut Clinic. Additionally, the investment will support the company’s pipeline targeting conditions associated with a disrupted gut microbiome, such as liver cirrhosis and hepatic encephalopathy (HE).
CEO Dr. James McIlroy on the Investment Impact
Dr. James McIlroy, CEO of EnteroBiotix, expressed the company’s vision to transform the standard of care for patients suffering from conditions linked to the gut microbiome. “This significant new investment will accelerate the development of our innovative product pipeline and propel us towards our goal of bringing these treatments to market,” McIlroy stated, highlighting the collaborative effort with new and existing partners.
About Irritable Bowel Syndrome (IBS)
IBS is a chronic gastrointestinal disorder characterized by symptoms such as abdominal pain, cramping, bloating, and altered bowel movements. It affects approximately one in eight individuals, carrying a substantial healthcare and economic burden.
The Functional Gut Clinic’s Role
The Functional Gut Clinic (FGC) is the UK’s leading independent provider of gastrointestinal physiology testing and diagnostics. Since its establishment in 2013, FGC has developed a robust R&D and clinical trials portfolio, contributing to the advancement of digestive health tests and treatments.
With this funding round, EnteroBiotix is set to further its mission of delivering innovative microbial therapeutics, offering new hope for patients with conditions linked to the gut microbiome.
